Tom Price resigns as HHS Secretary

HHS Secretary Tom Price, MD, has announced he’ll resign after criticism for taking publicly-funded charter flights when it appeared less expensive commercial travel was available.

The resignation comes a day after Price promised to reimburse the federal government for some costs related to the private flights, with a POLITICO investigation have finding he had racked up $1 million in publicly-funded travel costs, including flying on military aircraft on overseas trips. However, he’ll had pledged only pay back the cost of his seat on domestic charter flights, amounting to $52,000.

Price said the travel was legal and approved by HHS and didn’t apologize for using charter flights. In one example, he took a $25,000 charter flight from Washington, D.C. to Philadelphia when a commercial flight for the same route would’ve cost $725 per person.

“Despite this, I regret the concerns this has raised regarding the use of taxpayer dollars,” Price said.

The next day, President Donald Trump reiterated to reporters he was “not happy” with Price’s travel expenses and hinted he would have a decision on his job status later in the day. A statement from the White House Press Secretary said Price had offered his resignation to Trump sometime on Sept. 29, which Trump accepted.

Five Democrats in the House of Representatives had written to Price demanding he resign, saying his use of private flights represented a “gross misuse of public funds.” Other Democrats said paying back only for “his seat” on those flights was insufficient. Sen. Ron Wyden, D-Oregon, who as ranking Democrat on the Senate Finance Committee, opposed Price’s nomination, tweeted that until Price paid back the full cost of the charter flights, he “is still ripping off taxpayers.”

Price’s tenure at HHS had seen numerous attempts at repealing and replacing the Affordable Care Act fail to pass Congress, as well as criticism that his department had sought to “sabotage” the law by limiting enforcement of individual and employer mandates and cutting most of the advertising budget for the ACA exchanges.

The National Physicians Alliance (NPA), which had opposed his nomination and bashed groups like the American Medical Association for supporting it, had begun circulating online petitions calling for Price to resign.

“He has advocated cuts to programs impacting the most vulnerable Americans, while simultaneously wasting taxpayer resources,” wrote NPA President Manan Trivedi, MD, MPP. “Now almost one year later, we believe that his actions in office warrant resignation.”

Price was able to achieve one of his healthcare policy goals during his tenure at HHS, rolling back Obama-era mandatory bundled payment programs which he had opposed as a member of Congress.

Taking over as acting secretary will be Don Wright, MD, MPH. He currently serves as HHS’ deputy assistant secretary and director of the office for disease prevention and health promotion, a position he has held since Jan. 2012. Wright earned a medical degree from the University of Texas, a master’s degree in public health from the Medical College of Wisconsin and completed his family medicine residency training at Baylor College of Medicine.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.